Accessibility Menu
OncoSil Medical logo

OncoSil Medical(ASX) OSL

Market CapA$38.92MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2005)-98%
5 YearN/A
1 Year+5%
1 Month-8%
A$1.27
+0.79%
+0.01Today
OncoSil Medical last closing stock price
MetricPriceDate
Last closeAUD 1.262026-08-13
OncoSil Medical stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+4.13%AUD 1.212026-08-06
1 month-8.36%AUD 1.382026-07-14
3 month+180%AUD 0.452026-05-15
Year to date+29.9%AUD 0.972025-12-31
1 year+5%AUD 1.202025-08-13
Since inception-97.63%AUD 53.102005-08-15

OncoSil Medical Financials at a Glance

Market Cap

A$38.92MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$2.22M

Net Income (TTM)

-A$25.98M

EPS (TTM)

-A$0.95

P/E Ratio

-1.33

Dividend

A$0.00

Beta (Volatility)

0.01 (Low)

Price

A$1.27

Volume

67,148

Open

A$1.26

Previous Close

A$1.26

Daily Range

A$1.22 - A$1.29

52-Week Range

A$0.37 - A$2.09

Estimated Earnings Date

Aug 27, 2026

OSL News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About OncoSil Medical

OncoSil Medical Ltd is a medical device company focused on developing and commercializing localized radiation therapy for pancreatic and distal cholangiocarcinoma. The company's flagship product, OncoSil, is a single-use brachytherapy device designed to treat patients with locally advanced pancreatic cancer in conjunction with gemcitabine-based chemotherapy.

Products and Services
  • OncoSil: A brachytherapy device for localized radiation therapy
  • Research and development of innovative cancer treatment solutions
  • Collaboration with healthcare providers for clinical applications
Growth Outlook
  • Increasing global demand for effective cancer therapies supports market potential
  • Strategic partnerships may enhance product distribution and reach
  • Ongoing clinical trials aim to validate OncoSil's efficacy and safety
Financial Highlights
  • Recent quarterly revenue of AUD 782,895 shows growth potential
  • Cash and cash equivalents of AUD 2.85 million provide operational support
  • Current ratio of 2.05 indicates strong short-term financial health
OncoSil Medical Ltd operates in a critical sector, addressing significant unmet needs in cancer treatment. The company's innovative approach to localized radiation therapy positions it well within the healthcare landscape. With a focus on research and development, OncoSil aims to expand its product offerings and enhance treatment options for patients suffering from challenging cancers. The financial metrics indicate a foundation for growth, with a solid cash position and a favorable current ratio, suggesting the company is well-equipped to navigate its operational landscape. As the demand for effective cancer therapies continues to rise, OncoSil Medical Ltd presents an intriguing opportunity for potential investors interested in the healthcare sector.
AI Generated • Jul 22, 2026

Industry

Life Sciences Tools and Services

Sector

Health Care

CEO

Nigel Lange

Website

www.oncosil.com.au

Headquarters

Macquarie Park, NSW 2113, AU

OSL Financials

Key Financial Metrics (TTM)

Gross Margin

-295.91%

Operating Margin

-1153.72%

Net Income Margin

-969.26%

Return on Equity

-372.27%

Return on Capital

-488.08%

Return on Assets

-181.15%

Earnings Yield

-75.19%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$38.92MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

30.89M

Volume

67.15K

Avg. Volume

256.25K

Financials (TTM)

Gross Profit

-A$9.83M

Operating Income

-A$28.47M

EBITDA

-A$28.40M

Operating Cash Flow

-A$25.54M

Capital Expenditure

-A$214.96K

Free Cash Flow

-A$25.76M

Cash & ST Invst.

A$2.85M

Total Debt

A$42.47K

OncoSil Medical Performance Analysis

OncoSil Medical annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30AUD 231,789N/A
20232023-06-30AUD 367,67758.6%
20242024-06-30AUD 516,63240.5%
20252025-06-30AUD 1,170,793126.6%
OncoSil Medical sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-30387.4%
Q22024-12-317.1%
Q42025-06-3019.7%
Q22025-12-3142.4%
OncoSil Medical annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30AUD -4.04N/A
20232023-06-30AUD -3.77-6.6%
20242024-06-30AUD -2.14-43.4%
20252025-06-30AUD -1.37-35.7%
OncoSil Medical sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-303.4%
Q22024-12-31-5971.4%
Q42025-06-30-317.6%
Q22025-12-3166.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

A$782.90K

+790.1%

Gross Profit

-A$3.22M

-0.0%

Gross Margin

-4.12%

N/A

Market Cap

A$38.92MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$6.49M

N/A

Employees

6

N/A

Net Income

-A$4.53M

+24.8%

EBITDA

-A$6.94M

-7.0%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

A$2.85M

-41.6%

Total Debt

A$42.47K

-60.4%

Accounts Receivable

A$3.27M

+455.0%

Inventory

A$0.00

N/A

Long Term Debt

A$0.00

-100.0%

Short Term Debt

A$42.47K

-38.2%

Return on Assets

-1.81%

N/A

Return on Invested Capital

-4.00%

N/A

Free Cash Flow

-A$6.96M

-61.7%

Operating Cash Flow

-A$6.96M

-61.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
HMD.AXHeraMED Limited
A$0.04+0.00%
RHY.AXRhythm Biosciences Limited
A$0.08-2.47%
RHT.AXResonance Health Limited
A$0.05+0.00%
IDT.AXIDT Australia Limited
A$0.04-6.38%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$8.91-0.09%
SMCISuper Micro Computer
$39.16+0.04%
SPCXSpace Exploration Technologies
$141.29-0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.64+0.07%

Questions About OSL

What is the current price of OncoSil Medical?

OncoSil Medical is trading at A$1.27 per share.

What is the 52-week range for OncoSil Medical?

Over the past 52 weeks, OncoSil Medical has traded between A$0.37 and A$2.09.

How much debt does OncoSil Medical have?

As of the most recent reporting period, OncoSil Medical reported total debt of A$69.92K.

How much cash does OncoSil Medical have on hand?

OncoSil Medical reported A$5.11M in cash and cash equivalents in its most recent financial results.

What is OncoSil Medical’s dividend yield?

OncoSil Medical does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services